[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thalassemia-majors-beta-thalassemia-major\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thalassemia-majors-beta-thalassemia-major":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,63,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":17,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100632154","risk-factors-affecting-growth-in-thalassemic-children-at-auch-100632154",false,"NCT07509996","Risk Factors Affecting Growth in Thalassemic Children at AUCH","The Effect of Different Risk Factors on Growth Parameters of Thalassemic Patients in Assiut University Children Hospital","Inclusion Criteria:\n\n* Children aged 1 to 18 years diagnosed with β-thalassemia major based on hemoglobin electrophoresis or high-performance liquid chromatography (HPLC).\n* Receiving regular blood transfusions as part of standard management at AUCH.\n* Attending the hematology unit for at least one year prior to enrollment.\n\nExclusion Criteria:\n\n* • Children with other types of thalassemia.\n\n  * Presence of congenital diseases, chronic illnesses other than thalassemia (e.g., malignancy, tuberculosis, chronic hepatitis, congenital heart disease, chronic renal failure, epilepsy, diabetes mellitus), or primary endocrinopathies.\n  * Patients with other causes of short stature, such as hereditary bone dysplasia or systemic disorders.","ALL","12 Months","18 Years",{"count":20,"type":21},85,"ESTIMATED","OBSERVATIONAL","Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.",[25],"Thalassemia Majors (Beta-Thalassemia Major)","NOT_YET_RECRUITING","2026-03-28",{"date":29,"type":30},"2026-04-03","ACTUAL",{"date":32,"type":21},"2026-04-01",{"date":34,"type":21},"2027-05-01",{"name":36,"class":37},"Assiut University","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100615142","gonadal-function-in-thalassemic-patient-100615142","NCT07288762","Gonadal Function in Thalassemic Patient","Gonadal Function in Boys With Transfusion Depandant Beta Thalassemia","Inclusion Criteria:\n\n* transfusion depandant beta thalassemia\n* age 10 to 18 year old age\n\nExclusion Criteria:\n\n* age below 10 year old age or above 18 year old age\n* associated with another disease",true,"MALE","10 Years",{"count":49,"type":21},80,"Patient with transfusion depandant beta thalassemia with accumulation of iron in their body affect pituitary gland and gonades lead to impaired their functions .",[25],[53],"INSL3 or inhibin B hormone in transfusion depandant beta thalassemia","2025-12-04",{"date":56,"type":30},"2025-12-17",{"date":58,"type":21},"2025-12-07",{"date":60,"type":21},"2026-08-01",{"name":62,"class":37},"Sohag University",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100591456","the-effect-of-laughter-yoga-in-beta-thalassaemia-major-patients-a-randomised-controlled-trial-100591456","NCT06980662","The Effect of Laughter Yoga in Beta Thalassaemia Major Patients: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Diagnosed with Beta Thalassaemia major,\n* Over 18 years of age,\n* No hearing and communication problems,\n* The one with the smartphone\n* Routine treatment with iron chelators, folic acid and magnesium\n* Do not have a physical problem that will prevent yoga exercises (bleeding haemorrhoids, all kinds of hernia, persistent cough, incontinence, severe back pain, hypertension, major psychiatric diseases, pregnancy, flu, epilepsy, surgery in the last 3 months, etc.)\n* Depression-Anxiety-Stress scale scores of 10 and above for depression (depressed), 8 and above for anxiety (anxious), 15 and above for stress (stressed)\n* Beta thalassaemia major patients who volunteered to participate in the study will be included in the study sample\n\nExclusion Criteria:\n\n* Who doesn't practice laughter yoga\n* Changing the treatment regime\n* Patients who wish to withdraw from the study","65 Years",{"count":71,"type":21},60,"INTERVENTIONAL",[74],"NA","The aim of this study was to evaluate the effects of laughter yoga on Fatigue, Depression-Anxiety-Stress, Sleep quality, Haematological values and Blood transfusion number in Beta Thalassemia Major patients.",[77,25],"Beta Thalassemia Major",[79,80],"Nursing, Fatigue, Depression-Anxiety-Stress and Sleep quality","fatigue","2025-05-12",{"date":83,"type":30},"2025-05-20",{"date":85,"type":21},"2025-06-01",{"date":87,"type":21},"2025-08-31",{"name":89,"class":37},"Ataturk University",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":47,"enrollmentInfo":98,"targetDuration":4,"studyType":72,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100572534","clinical-study-of-super-transplantation-in-the-treatment-of-severe--thalassemia-100572534","NCT06734520","Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia","Inclusion Criteria:\n\n1. Diagnosis of severe β -thalassemia\n2. Age between 7-10 years old, male and female; Weight \\\u003C 40kg\n3. The patient has or does not have an HLA-compatible or semi-compatible donor, but unconditional transplantation or refusal of blood stem cell transplantation; Patients with thalassemia gene therapy without conditions or refusal;\n4. There are fully compatible or incompatible HLA donors, and the physical examination meets the donor conditions;\n5. The patient and family members agree to receive hypertransplant therapy and sign a written informed consent prior to the transplant trial.\n\nExclusion Criteria:\n\n1. Mental patients;\n2. Participants in other drug clinical trials within the past 1 month;\n3. There are no suitable HLA-incompatible donors.\n4. Other researchers decide that it is not suitable to participate in this researcher.","7 Years",{"count":99,"type":21},3,[74],"This is a single-arm, open label, phase 1 study in subjects with beta-thalassemia. This study will evaluate the safety and efficacy of preconditioning-free super-transplantation on beta-thalassemia pediatric patients.",[25,103],"Haplo-identical Donors","RECRUITING","2024-12-12",{"date":107,"type":30},"2024-12-16",{"date":109,"type":30},"2024-10-01",{"date":111,"type":21},"2029-07-01",{"name":113,"class":37},"Guangzhou Women and Children's Medical Center",2]